Time to event analysis
| . | Median follow-up (months, range) . | Median PFS (months; 95% CI) . | Median OS (months; 95% CI) . | 12-mo OS (95% CI) . |
|---|---|---|---|---|
| All patients (N = 67) | 15.0 (3.7-26.4) | 8.6 (7.5-13.9) | Not reached | 65% (51-76%) |
| Dose level 1, 1.5, 2 mg (N = 12) | 24.1 (3.7-26.4) | 4.6 (3.3-8.0) | 9 (5.2-not reached) | 44% (15-70%) |
| Dose level 2.5 mg (N = 55) | 14.8 (6.1-21.4) | 10.4 (7.8-15.8) | Not reached | 69% (54-81%) |
| Relapsed after lenalidomide (N = 18) | 12.7 (7.2-21.4) | 15.7 (12.8-20.7) | Not reached | 88% (60-97%) |
| Refractory to lenalidomide (N = 37) | 15.3 (6.1-21.4) | 8.6 (7.5-13.9) | Not reached | 60% (41-75%) |
| Refractory to lenalidomide and bortezomib (N = 16) | 15.8 (6.6-21.4) | 8.6 (4.8-not reached) | Not reached | 67% (37-85%) |
| . | Median follow-up (months, range) . | Median PFS (months; 95% CI) . | Median OS (months; 95% CI) . | 12-mo OS (95% CI) . |
|---|---|---|---|---|
| All patients (N = 67) | 15.0 (3.7-26.4) | 8.6 (7.5-13.9) | Not reached | 65% (51-76%) |
| Dose level 1, 1.5, 2 mg (N = 12) | 24.1 (3.7-26.4) | 4.6 (3.3-8.0) | 9 (5.2-not reached) | 44% (15-70%) |
| Dose level 2.5 mg (N = 55) | 14.8 (6.1-21.4) | 10.4 (7.8-15.8) | Not reached | 69% (54-81%) |
| Relapsed after lenalidomide (N = 18) | 12.7 (7.2-21.4) | 15.7 (12.8-20.7) | Not reached | 88% (60-97%) |
| Refractory to lenalidomide (N = 37) | 15.3 (6.1-21.4) | 8.6 (7.5-13.9) | Not reached | 60% (41-75%) |
| Refractory to lenalidomide and bortezomib (N = 16) | 15.8 (6.6-21.4) | 8.6 (4.8-not reached) | Not reached | 67% (37-85%) |